Researchers halt enrollment in trial of Avastin

Share this article:
Following the sudden death of four patients for reasons unrelated to cancer, researchers decided to stop enrolling new patients in a clinical trial involving Genentech's cancer drug Avastin. Published reports say the unexpected fatalities are the first in clinical trials of Avastin, although it's not clear to what extent the drug was responsible. The deaths came during a trial in which Avastin was used along with a chemotherapy regimen called Xelox, composed of capecitabine and oxaliplatin. Overall there were seven non-cancer-related deaths in the Avastin/Xelox group, two from heart trouble. The cause of death of three remains unknown, and Genentech said it had no data on the other two patients. Roche, which holds a majority stake in Genentech, said it has suspended enrollment while experts review additional safety data. Avastin had 2005 sales of $1.1 billion.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.